PTC THERAPEUTICS, INC. — fact timeline

PTC THERAPEUTICS, INC. incurred convertible notes of $550,000,000 with U.S. Bank Trust Company, National Association at 0.0% maturing June 15, 2031.

“On June 18, 2026, PTC Therapeutics, Inc. (the “Company”) completed its previously announced private offering of $550,000,000 aggregate principal amount of its 0.0% Convertible Senior Notes due 2031 (the “Notes”) and entered into an indenture with U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), governing the Notes (the “Indenture”).”

PTC THERAPEUTICS, INC. entered into Indenture with U.S. Bank Trust Company, National Association valued at $550,000,000 0.0% Convertible Senior Notes due 2031 (effective 2026-06-18).

“On June 18, 2026, PTC Therapeutics, Inc. (the “Company”) completed its previously announced private offering of $550,000,000 aggregate principal amount of its 0.0% Convertible Senior Notes due 2031 (the “Notes”) and entered into an indenture with U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), governing the Notes (the “Indenture”).”

Alethia Young resigned as Member of the board of directors at PTC THERAPEUTICS, INC..

“On June 8, 2026, Alethia Young, a member of the board of directors (the "Board") of PTC Therapeutics, Inc. (the "Company"), notified the Company of her resignation from the Board effective June 8, 2026.”

PTC THERAPEUTICS, INC. shareholders approved Non-binding advisory proposal on named executive officer compensation at the 2026-06-02 meeting.

“The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 71,166,204 votes “For,” 1,492,801 votes “Against,” 24,290 votes “Abstained,” and 3,858,311 broker non-votes.”

PTC THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders with 76,170,292 votes “For,” 355,794 votes “Against,” and 15,520 votes “Abstained.””

PTC THERAPEUTICS, INC. shareholders approved Election of four Class I directors at the 2026-06-02 meeting.

“The Company held its Annual Meeting on June 2, 2026 (the “Annual Meeting”). The results for the votes regarding each proposal at the Annual Meeting are set forth below.”

PTC THERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: revenue $273 million, net income Net loss was $2.8 million for the first quarter of 2026. Guidance raised.

“PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results – First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise”

PTC THERAPEUTICS, INC. amended Amendment No. 2 to Amended and Restated Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at $240.0 million in upfront cash consideration (effective 2025-12-29).

“On December 29, 2025, PTC Therapeutics, Inc. (the “Company”), Royalty Pharma Investments 2019 ICAV (“RPI”), and, for the limited purposes set forth in the Purchase Agreement (as defined below), Royalty Pharma plc, entered into an Amendment No. 2 to Amended and Restated Royalty Purchase Agreement (the “Amendment”), which amends that certain Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023, as amended by Amendment No. 1 dated June 17, 2024 (the “Purchase Agreement”).”

PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2024 results: revenue $210.1 million, net income $91.6 million. Guidance reaffirmed.

“many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin." ​ Key Corporate Updates: ● First quarter 2024 total revenue of $210 million ● First quarter 2024 revenue for the DMD franchise was $161 million o TranslarnaTM (ataluren) net product revenue was $104 million, driven by new patients in existing geographies”

PTC THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $307.1 million for the fourth quarter of 2023... Total revenue was $937.8 million for full year 2023.

“PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2023.”

PTC THERAPEUTICS, INC. reported full year 2024 results: revenue $600 million to $850 million. Guidance initiated.

“PTC anticipates total revenues for the full year 2024 to be between $600 million and $850 million.”

PTC THERAPEUTICS, INC. reported full year 2023 results: revenue $946 million.

“Total unaudited net revenue for full year 2023 was approximately $946 million.”

PTC THERAPEUTICS, INC. reported the third quarter ending September 30, 2023 results: revenue $196.6 million. Guidance reaffirmed.

“Total revenues were $196.6 million for the third quarter of 2023, compared to $217.1 million for the third quarter of 2022.”

PTC THERAPEUTICS, INC. terminated Credit Agreement valued at $302.1 million (effective 2023-10-19).

“On October 19, 2023, the Company terminated the Credit Agreement, dated October 27, 2022, by and among the Company, as the borrower, each subsidiary of the Company from time to time party thereto, as guarantors, the lenders from time to time party thereto and Wilmington Trust National Association, as administrative agent (the "Credit Agreement").”

PTC THERAPEUTICS, INC. announced a restructuring with charges of approximately $21.0 million affecting early-stage research and gene therapy manufacturing and associated selling, general and administrative functions in the United States (approximately 25%).

“On September 28, 2023, PTC Therapeutics, Inc. (the “Company”) announced further strategic prioritization following the continued review of its portfolio that the Company began in May 2023. In connection with the strategic prioritization, on September 28, 2023, the Company committed to a reduction in workforce of approximately 25%, which will primarily affect employees in the United States, including those employees involved in early-stage research and gene therapy manufacturing and associated selling, general and administrative functions. The Company plans to substantially complete the reduction in workforce by January 15, 2024. Affected employees will be offered separation benefits, including severance payments along with temporary healthcare coverage assistance and other benefits. The Company estimates that the employee severance and benefit costs along with required pre-termination associated payments and benefits will be approximately $21.0 million, substantially all of which are e”

PTC THERAPEUTICS, INC. reported financial results for the second quarter ending June 30, 2023.

“On August 3, 2023, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.”

Pierre Gravier was appointed as Chief Financial Officer at PTC THERAPEUTICS, INC..

“On July 13, 2023, the Board of Directors of PTC Therapeutics, Inc. (the “Company”) appointed Pierre Gravier, age 38, as Chief Financial Officer, effective as of July 13, 2023.”

PTC THERAPEUTICS, INC. shareholders approved Non-binding advisory proposal on named executive officer compensation at the 2023-06-06 meeting.

“The non-binding advisory proposal on named executive officer compensation was approved by the Company's stockholders with 65,318,123 votes "For,” 1,464,756 votes “Against,” 21,688 votes “Abstained,” and 2,986,852 broker non-votes.”

PTC THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-06 meeting.

“The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified by the Company's stockholders with 69,370,823 votes "For,” 406,974 votes “Against,” and 13,622 votes “Abstained.””

PTC THERAPEUTICS, INC. shareholders approved Election of four Class I directors at the 2023-06-06 meeting.

“The stockholders of the Company elected four Class I directors, each to hold office until the Company's 2026 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows: ​ ​ ​ ​ ​ Director For Withheld Broker Non-Votes William F. Bell, Jr. 63,215,577 3,588,990 2,986,852 Matthew B. Klein, M.D., M.S., F.A.C.S. 66,478,887 325,680 2,986,852 Stephanie S. Okey, M.S. 63,816,731 2,987,836 2,986,852 Jerome B. Zeldis, M.D., Ph.D. 58,377,983 8,426,584 2,986,852”

PTC THERAPEUTICS, INC. announced a restructuring with charges of approximately $7.0 million affecting gene therapy platform; primarily affects employees in the United States (reduction in workforce of approximately 8%).

“other benefits. The Company estimates that the employee severance and benefit costs along with required pre-termination associated payments and benefits will be approximately $7.0 million, substantially all of which are expected to be cash expenditures. T he estimate of costs that the Company expects to incur, and the timing thereof, are subject to a number of”

Emily Hill was terminated as Chief Financial Officer at PTC THERAPEUTICS, INC..

“On May 20, 2023, the Company informed Emily Hill, its Chief Financial Officer, that her employment will be terminated effective as of August 20, 2023, and effective immediately she will cease to serve as the Company's Chief Financial Officer.”

PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2023 results: revenue $220.4 million. Guidance reaffirmed.

“this Item 2.02. ​ --- EX-99.1 (EX-99.1) --- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results – First-quarter 2023 total revenue of $220 million, representing 48% year-over-year growth - ​ – Readouts from four clinical studies expected in second quarter of 2023, three of which are registration-directed – ​ SOUTH”

Matthew B. Klein was appointed as Chief Executive Officer and President at PTC THERAPEUTICS, INC..

“the Board of Directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”) appointed Dr. Matthew B. Klein, age 51, as Chief Executive Officer and President and a member of the Board, effective as of March 22, 2023.”

Stuart W. Peltz retired as Chief Executive Officer at PTC THERAPEUTICS, INC..

“Dr. Stuart W. Peltz, who provided the Board with notice on March 22, 2023 of his decision to retire as Chief Executive Officer and as a member of the Board, in each case, effective as of March 22, 2023.”

PTC THERAPEUTICS, INC. reported the fiscal year ended December 31, 2022 results: revenue $698.8 million. Guidance reaffirmed.

“Total revenues were $698.8 million for the full year 2022”

PTC THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $167.4 million. Guidance reaffirmed.

“Total revenues were $167.4 million for the fourth quarter of 2022”

PTC THERAPEUTICS, INC. reported fiscal year ending December 31, 2022 results: revenue total unaudited net revenue of approximately $710 million. Guidance initiated.

“On January 9, 2023, PTC Therapeutics, Inc. (the “Company”) issued a press release (the “press release”) announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2022, including that the Company expects to report (i) total unaudited net revenue of approximately $710 million”

PTC THERAPEUTICS, INC.: Amended and restated bylaws to eliminate stockholder list requirement at meetings, permit remote meetings, update proxy rules, and add exclusive forum provisions (effective 2022-12-05).

“On December 5, 2022, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.”

Dawn Svoronos resigned as director at PTC THERAPEUTICS, INC..

“On December 5, 2022, Dawn Svoronos, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”), notified the Company of her resignation from the Board effective December 6, 2022.”

PTC THERAPEUTICS, INC. incurred credit facility of up to $950.0 million with Blackstone at adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rat maturing seven years from the Closing Date.

“Debt Facility On October 27, 2022 (the “Closing Date”), PTC Therapeutics, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company”

PTC THERAPEUTICS, INC. entered into Stock Purchase Agreement with certain entities affiliated with the Lenders (the “Purchasers”) valued at approximately $50.0 million (effective 2022-10-27).

“the Company and certain entities affiliated with the Lenders (the “Purchasers”) also entered into a stock purchase agreement on the Closing Date (the “Stock Purchase Agreement”) for the sale and issuance of 1,095,290 shares of common stock (the “Shares”) to the Purchasers at a price of $45.65 per share, for an aggregate purchase price of approximately $50.0 million”

PTC THERAPEUTICS, INC. entered into Credit Agreement with funds and other affiliated entities advised or managed by Blackstone Life Sciences Advisors L.L.C. and Blackstone Alternative Credit Advisors LP valued at up to $950.0 million (effective 2022-10-27).

“On October 27, 2022 (the “Closing Date”), PTC Therapeutics, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing”

PTC THERAPEUTICS, INC. reported the quarter ended September 30, 2022 results: revenue $217.1 million, net income $(109.3) million. Guidance raised.

“into this Item 2.02. ​ --- EX-99.1 (EX-99.1) --- PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results - Total quarterly revenue of $217 million, representing 57% year-over-year growth – - 2022 DMD revenue guidance and low end of total revenue guidance increased - - Strategic financing with Blackstone with up to $1”